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Background. Rotavirus vaccine schedules may impact vaccine response among children in low- and middle-income countries 
(LMICs). Our objective was to review the literature evaluating the effects of monovalent (RV1) or pentavalent rotavirus vaccines 
schedules on vaccine response.
Methods. We searched PubMed, Web of Science, Embase, and ClinicalTrials.gov for eligible trials conducted in LMICs compar-
ing ≥2 vaccine schedules and reporting immunologic response or efficacy. We calculated seroconversion proportion differences and 
geometric mean concentration (GMC) ratios with 95% confidence intervals.
Results. We abstracted data from 8 eligible trials of RV1. The point estimates for seroconversion proportions difference ranged 
from −0.25 to −0.09 for the 6/10-week schedule compared with 10/14. The range for the 6/10/14- compared with 10/14-week sched-
ule was −0.02 to 0.10. Patterns were similar for GMC ratios and efficacy estimates.
Conclusions. The commonly used 6/10-week RV1 schedule in LMICs may not be optimal. Further research on the effect of 
rotavirus schedules using clinical endpoints is essential.
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Rotavirus vaccination has been recommended for all infants 
worldwide [1]. As of May 2016, 81 countries, including 44 low- 
and middle-income countries (LMICs), have introduced rota-
virus vaccines into their national immunization programs [2]. 
Most of these countries use 1 of the 2 oral rotavirus vaccines avail-
able globally: the monovalent ([RV1] Rotarix; GlaxoSmithKline 
Biologicals, Rixensart, Belgium) or pentavalent ([RV5] RotaTeq; 
Merck & Co., Inc.; Kenilworth, NJ) rotavirus vaccine [3, 4].
The efficacy of RV1 and RV5 is low in LMICs (39%–59%) 
[5–7] and could be due to a number of factors including the 
following: interference by maternally acquired antibodies, gut 
microbiota composition, interference from oral polio vaccine 
(OPV), and/or altered enteric immunity due to the burden of 
coinfections and malnutrition among infants in LMICs [8]. 
Potential interference by maternal antibodies seems plausible 
because some studies have reported high correlations (0.57–
0.86) between anti-rotavirus immunoglobulin (Ig) G antibody 
levels in mothers and infants in LMICs [9, 10] and the poten-
tial for IgG antibodies to interfere with RV1 immune response 
[11, 12]. Infants in LMICs are often undernourished and have 
repeated exposure to a variety of enteric pathogens. This may 
result in chronic environmental enteropathy, which can lead to 
altered enteric immunity [13]. In addition, infants in LMICs 
are administered OPV rather than the inactivated polio vac-
cine, and OPV has been reported to interfere with the immune 
response to both RV1 and RV5 [14, 15]. These factors combined 
could require different timing and number of doses of RV1 or 
RV5 to improve the performance of these vaccines in LMICs.
Rotavirus vaccines schedules (the timing and number of doses 
received) are easily measured and were varied among some trials 
conducted in LMICs. To assess the current literature on the poten-
tial impact of the timing of vaccine schedules on vaccine response, 
we conducted a systematic review of randomized control trials 
conducted before 2016 that compared 2 or more rotavirus vaccine 
schedules of either RV1 or RV5 among infants in LMICs.
METHODS
Study Selection
This review was conducted after PRISMA guidelines [16]. 
Only randomized Phase II, III, and IV trials of RV1 or RV5 
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conducted in a LMIC were eligible for this review (PICOS Table 
in Supplemental Table 1). Trials had to be conducted among 
infants who were randomized to receive a complete RV1 or RV5 
series (≥2 doses of RV1 or ≥3 doses of RV5) with ≥2 different 
dosing schedules of treatment; final rotavirus vaccine dose had 
to be given by 24 weeks (RV1) or 32 weeks (RV5) of age. A dif-
ferent dosing schedule was defined as a change in the number 
or timing of doses of RV1 or RV5 (eg, for RV1, 6/10- versus 
6/10/14-week schedules). All trials had to report measures of 
immunogenicity (anti-rotavirus IgA antibody concentrations 
as either seroconversion proportion, geometric mean concen-
trations or geometric mean titers) or efficacy against severe 
rotavirus gastroenteritis (RVGE) (polymerase chain reaction 
[PCR]-confirmed, wild-type) and be written in English.
Data Sources and Searches
Medline (using PubMed), Embase, and Web of Science were 
searched on January 19, 2016 for the terms “Rotarix” or 
“RIX4414” or “RotaTeq” or “WC3” and the name of all the 
LMICs (Supplemental Table 2). In addition, ClinicalTrials.gov 
was searched on February 9, 2016 using the term “rotavirus.” 
Supplemental Table 2 contains the exact searches performed.
We removed duplicate articles/records from the search results. 
Before title and abstract review of each article, we searched for 
missing abstracts manually. Articles without abstracts available 
were automatically advanced to full-text review. Two reviewers 
(J.F.G. and L.M.G.) screened the title and abstract of each article 
according to the PICOS table criteria. We retrieved and dually 
reviewed full-texts of articles if either reviewer determined 
the abstract should be evaluated further. Dual review was also 
completed for studies and published articles identified in the 
ClincalTrials.gov search. Any discrepancies between reviewers 
were resolved by a third reviewer (S.B.-D.).
Data Abstraction and Quality Assessment
We abstracted data from all trials meeting the inclusion cri-
teria. Immunogenicity and efficacy data were abstracted into 
a standardized table by J.F.G. and then verified by L.M.G.  for 
each trial. For RV1, seroconversion proportion was defined as 
the proportion of participants with anti-rotavirus IgA antibody 
concentrations ≥20 U/mL 1  month after completing all RV1 
doses (among those who were seronegative before vaccination). 
For RV5, seroconversion proportion was defined as the propor-
tion of participants with at least a 3-fold rise in anti-rotavirus 
IgA antibody titer from baseline to 1 month after completing 
all RV5 doses. One-month geometric mean concentrations or 
titers were abstracted for RV1 and RV5, respectively. If blood 
samples were not collected in the month after vaccination, 
2-month seroconversion proportion and geometric mean con-
centration or titer were abstracted.
To assess the potential bias of each included trial, J.F.G. and 
R.P.W.  independently reviewed each trial using a standard-
ized risk of bias tool. Any discrepancies in the responses were 
discussed until consensus was reached. Each trial was classified 
as “low,” “medium,” or “high” risk of bias.
For studies missing sample size for immunogenicity end-
points, corresponding authors were contacted and asked to pro-
vide the sample size. If sample sizes were unavailable, they were 
estimated from the available information and identified as such 
in the results. Otherwise, raw data related to immunologic and 
clinical endpoints were presented as they were published.
Data Analysis
Differences in seroconversion proportions with corresponding 
95% confidence intervals and ratios of geometric mean con-
centrations or titers with corresponding 95% confidence inter-
vals were estimated between groups with different RV1 or RV5 
schedules. This was done using the reported or estimated sam-
ple size, seroconversion proportion, and geometric mean con-
centrations or titers extracted from each trial. Because different 
schedules could be evaluated across trials, the most commonly 
used schedules were compared with a common referent group 
and were presented in figures whereas comparisons of less 
common schedules were presented in tables. All analyses were 
conducted using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
There were 822 articles and 183 ClinicalTrials.gov records 
identified through the searches (Supplemental Figure 1). After 
deduplication, 639 abstracts from the database search were 
screened, 580 of which were excluded. Review of 59 full-text 
articles and 183 ClinicalTrials.gov records resulted in the inclu-
sion of 10 articles [5, 11, 12, 17–23] representing 8 unique trials.
Missing Information
In National Clinical Trial (NCT)00346892 [21], sample size was 
unavailable, but the number randomized was provided. We used 
an exclusion/dropout rate of 30%, which was the exclusion/
dropout rate in another trial (NCT00383903 [23]) conducted in 
South Africa around the same time period, to estimate the sample 
sizes of each group. Likewise, we were unable to determine the 
sample size for the immunogenicity cohort in Malawi from trial 
NCT00241644 [5, 18]. The sample size was estimated using the 
estimate of seroconversion proportion and 95% confidence inter-
val to solve for the standard error and sample size. In addition, one 
trial, Clinical Trials Registry of India (CTRI)-2012-02-002454, 
did not report 95% confidence intervals for seroconversion pro-
portion [19]. Exact confidence intervals were estimated using the 
sample size and seroconversion proportion estimate.
Study Characteristics
Of the 8 included trials, all evaluated different schedules of RV1 
(Table 1) and none evaluated different schedules of RV5. Four of 
these trials were Phase II, 1 Phase III, and 3 Phase IV. The earliest 
trial began data collection in 2001 and the latest in 2012. Most 
trials evaluated the lyophilized formulation of RV1 given at the 
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licensed concentration concomitantly with routine vaccines, 
including OPV. Most trials had similar inclusion and exclusion 
criteria for the study populations. Half of the trials were con-
ducted in Asian LMICs whereas the other half were conducted 
in African LMICs. Several of the trials conducted in Africa were 
conducted in South Africa. All trials had medium or low risk of 
bias (Supplemental Table 3). Trials (N = 3) with a medium risk 
of bias had moderate to high attrition and/or did not adequately 
describe the method of treatment randomization.
Intermediate Outcomes
Seroconversion proportions and geometric mean concentra-
tions were available for all trials (Table 2). The seroconversion 
proportion ranged from approximately 0.3 to approximately 0.8 
across the different schedules evaluated by country and trial. 
Geometric mean concentrations of postimmunization anti-ro-
tavirus IgA ranged from 19.7 U/mL to 176.3 U/mL across dif-
ferent schedules by country and trial.
Differences in Seroconversion Proportions
Differences in seroconversion proportions comparing 6/10- 
versus 10/14-week schedules and 6/10/14- versus 10/14-week 
schedules are presented in Figure 1. In general, seroconversion 
proportions for the 6/10-week schedule were lower than for the 
10/14-week schedule. Only 2 of these estimated differences, 
trial NCT00346892 in South Africa [21] and NCT01575197 
in Ghana [11], were statistically significantly different than the 
null (no difference between schedules). By contrast, serocon-
version proportions for the 6/10/14-week schedule were simi-
lar or slightly higher than seroconversion proportions for the 
10/14-week schedule.
Differences in the less commonly used schedules are pre-
sented in Table  3. There was no difference in seroconversion 
proportions between the 6/10/14- and 6/10/14/18/22-week 
schedules in India. However, there was a statistically significant 
lower seroconversion proportion for the 8.8/13.2-week sched-
ule compared with the 8.6/17.4-week schedule in Vietnam. The 
seroconversion proportion for the 6.5/15.1-week schedule was 
lower than the 10.6/15.2-week schedule, although not statisti-
cally significant.
Ratios of Geometric Mean Concentrations
The ratios of geometric mean concentration levels comparing 
the 6/10- and 6/10/14-week schedules to the 10/14-week sched-
ule are presented in Figure  2. These ratios followed a similar 
pattern to the differences in seroconversion proportions. In gen-
eral, the geometric mean concentration was lower, although not 
statistically significantly lower, for the 6/10- versus 10/14-week 
schedules. Similar to the results for difference in seroconversion 
proportion, the geometric mean concentrations were similar or 
slightly higher for 6/10/14- versus 10/14-week schedules.
For less commonly used schedules, the geometric mean con-
centration was significantly lower for 8.8/13.2-week schedule 
compared with the 8.6/17.4-week schedule. The responses were Tri
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Dierence
(95% CI)
–0.09 (–0.27, 0.09) NCT01199874 Pakistan
NCT01199874 Pakistan
NCT01575197 Ghana
NCT01575197 Ghana
NCT00241644 Malawi†
NCT00346892 South Africa*†
NCT00241644 South Africa
NCT00383903 South Africa§
NCT00346892 South Africa*†‡
–0.17 (–0.27, –0.07)
–0.25 (–0.44, –0.06)
–0.12 (–0.31, 0.07)
–0.02 (–0.19, 0.15)
0.06 (–0.05, 0.17)
0.10 (–0.06, 0.26)
0.10 (–0.07, 0.26)
0.00 (–0.12, 0.12)
–0.4 –0.2 0.2
Seroconversion Dierence (95% CI)
6/10/14 vs. 10/14 6/10 vs. 10/14
0.40.0
Trial Number and Country
Figure  1. One-month seroconversion proportion differences comparing different monovalent (RV1) rotavirus vaccine schedules from 5 trials conducted in low- and 
middle-income countries with concomitantly administered oral polio vaccines unless otherwise indicated. *RV1 viral concentration 105.6; †Estimated sample size used; 
‡Concomitant inactivated polio vaccine; §2-month seroconversion difference. CI, confidence interval.
Table 2. One-Month Seroconversion Percentage and GMCs by Trial and Country for Different Schedules of the Monovalent Rotavirus Vaccine Administered 
Concomitantly With Routine Vaccines, Including Oral Polio Vaccines Unless Otherwise Indicated
Trial Number Trial Month/Year Location Schedule N Seroconversiona % (95% CI) GMC (U/mL) (95% CI)
NCT00346892b South Africa 6/10 64d 36 (23–50) 28.1 (18.2–43.2)
November/2001–Oct/2003 10/14 63d 61 (43–76) 48.6 (29.9–78.9)
6/10c 41d 43 (29–58) 32.6 (20.7–51.3)
10/14c 42d 55 (39–70) 56.7 (32.5–98.9)
NCT00383903 South Africa 6/10/14 133 44.4 (35.8–53.2)e 30.7 (24.0–39.3)e
September/2003–February/2004 10/14 131 44.3 (35.6–53.2)e 29.3 (23.0–37.3)e
NCT00345956f Vietnam 8.8/13.2 130 56.2 (47.2–64.8) 48.7 (36.1–65.8)
September/2006–March/2007 8.6/17.4 119 81.5 (73.4–88.0) 176.3 (123.8–251.1)
NCT00432380f Philippines 6.5/15.1 120 59.2 (49.8–68.0) 75.6 (52.5–109.0)
March/2007–September/2007 10.6/15.2 120 70.0 (61.0–78.0) 68.0 (50.1–92.1)
NCT00241644 South Africa 6/10/14 66 66.7 (54.0–77.8) 94.3 (56.5–157.4)
October/2005–July/2007 10/14 70 57.1 (44.7–68.9) 59.4 (37.5–93.9)
Malawi 6/10/14 83d 57.1 (42.2–71.2) 51.2 (26–102)
10/14 68d 47.2 (30.4–64.5) 63.0 (36–109)
NCT01199874 Pakistan 6/10 46 29.7 (23.1–37.3) 19.7 (16.2–23.9)
April/2011–September/2012 6/10/14 62 36.7 (29.8–44.2) 25.8 (20.5–32.5)
10/14 60 38.5 (31.2–46.3) 24.4 (19.5–30.6)
CTRI-2012-02-002454c India 6/10/14 15 46.7 (21.3–73.4)g 72.9 (30.9–172.3)
March/2012–December/2012 6/10/14/18/22 22 45.5 (24.4–67.8)g 60 (35.3–102.2)
NCT01575197 Ghana 6/10 142 28.9 (22.1–36.8) 22.5 (17.4–28.2)
September/2012–February/2013 6/10/14 143 43.4 (35.5–51.6) 32.6 (24.7–43.2)
10/14 139 37.4 (29.8–45.7) 26.5 (20.7–34.0)
Abbreviations: CI, confidence interval; CTRI, Clinical Trials Registry of India; GMC, geometric mean concentration; Ig, immunoglobulin; NCT, National Clinical Trial.
aPercentage of seronegative participants with postvaccination anti-rotavirus IgA antibody concentrations of ≥20 U/mL.
bVaccine with viral concentration of 1 × 105.6 median cell culture infective dose.
cConcomitant inactivated polio vaccine.
dExact sample size not reported; sample size estimated.
eTwo-month seroconversion percentage/GMC.
fLiquid formulation of vaccine.
gExact 95% CI estimated.
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similar or slightly higher for the 6/10/14-week schedule com-
pared with the 6/10/14/18/22-week schedule. The responses 
were also similar or slightly higher for the 6.5/15.1-week sched-
ule compared with the 10.6/15.2-week schedule.
Comparison of Efficacy
One trial (NCT00241644 [5, 18, 20, 22]), conducted in South 
Africa and Malawi, reported vaccine efficacies by schedule using 
clinical outcomes (Table 4). In South Africa, the 6/10/14-week 
schedule had slightly higher efficacy compared with the 10/14-
week schedule. However, these efficacy estimates, particularly 
for the second year and cumulative 2-year efficacy, had large 
variability. In Malawi, the efficacy for the 6/10/14-week sched-
ule was largely indistinguishable from the 10/14-week schedule 
for the first-year efficacy, but the 6/10/14-week schedule had 
a numerically higher efficacy compared with the 10/14-week 
schedule during the second year, although the estimates were 
very imprecise.
DISCUSSION
Overall, a small body of literature reported the effect of RV1 
or RV5 schedules on vaccine immunogenicity or efficacy in 
LMICs. We identified 8 trials, all of which evaluated different 
schedules of RV1. These studies had relatively similar inclusion 
and exclusion criteria.
In general, the 6/10-week schedule was not as immunogenic 
as the 10/14-week schedule in LMICs. A 3-dose RV1 schedule 
at 6/10/14 weeks had similar or slightly higher immunogenicity 
and efficacy compared with a 2-dose schedule at 10/14 weeks. 
Table 3. Summary of Seroconversion Proportion Differences and Ratios of GMCs by Trial and Country of the Monovalent Rotavirus Vaccine for Vaccine 
Schedules Less Commonly Reported
Trial Number
Trial Month/Year Location Schedule Seroconversion Proportion Difference (95% CI) Ratio of GMC (95% CI)
CTRI-2012-02-002454a India 6/10/14 0.01 (−0.32 to 0.34) 1.2 (0.4 to 3.3)
March/2012–December/2012 6/10/14/18/22 (Reference) (Reference)
NCT00345956b Vietnam 8.8/13.2 −0.25 (−0.36 to −0.14) 0.3 (0.2 to 0.4)
September/2006–March/2007 8.6/17.4 (Reference) (Reference)
NCT00432380b Philippines 6.5/15.1 −0.11 (−0.23 to 0.01) 1.1 (0.7 to 1.8)
March/2007–September/2007 10.6/15.2 (Reference) (Reference)
Abbreviations: CI, confidence interval; CTRI, Clinical Trials Registry of India; GMC, geometric mean concentration; NCT, National Clinical Trial. 
aConcomitant inactivated polio vaccine.
bLiquid formulation of vaccine.
GMC Ratio
(95% CI)
NCT01199874 Pakistan
NCT01199874 Pakistan
NCT01575197 Ghana
NCT01575197 Ghana
NCT00241644 Malawi†
NCT00346892 South Africa*†
NCT00241644 South Africa
NCT00383903 South Africa§
NCT00346892 South Africa*†‡
1.0 (0.7, 1.5)
1.6 (0.8, 3.2)
0.8 (0.3, 2.0)
1.2 (0.8, 1.8)
1.1 (0.8, 1.5)
0.6 (0.3, 1.2)
0.6 (0.3, 1.1)
0.6 (0.5, 0.9)
0.8 (0.6, 1.1)
0.25 0.5 1 2 4
Ratio of  Geometric Mean Concentrations (95% CI)
6/10/14 vs. 10/146/10 vs. 10/14
Trial Number and Country
Figure 2. One-month ratios of geometric mean concentrations comparing different monovalent (RV1) rotavirus vaccine schedules from 5 trials conducted in low- and 
middle-income countries with concomitantly administered oral polio vaccines unless otherwise indicated. *RV1 viral concentration 105.6; †Estimated sample size used; 
‡Concomitant inactivated polio vaccine; §2-month ratio of GMCs. CI, confidence interval; GMC, geometric mean concentration.
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However, as mentioned previously, this was a relatively small 
body of evidence, and the estimates for each schedule within 
each trial had a large amount of variability. Consequently, mod-
erate differences that appear between different vaccine sched-
ules may be due to random variability. More importantly, these 
studies, in large part, relied on immunogenic assessment of the 
response to the vaccine. Currently, there is no known correlate of 
protection for anti-rotavirus IgA levels [24, 25]. Therefore, even 
an association between vaccine schedule and immunogenicity 
does not provide evidence of a difference in disease protection. 
However, the pattern observed in the immunogenicity data was 
similar to the pattern seen with clinical outcomes in one trial, 
although the 6/10-week and 10/14-week schedules were not 
compared using clinical outcomes.
The results of this compiled evidence are consistent with 
the hypothesis that immune response to vaccination may be 
dampened or negated by maternal antibodies, differences in 
profiles of microbiota, or other immunologic factors. However, 
by assessing vaccine schedule alone, it is impossible to know 
the mechanism through which this effect, if it exists, occurs. 
Maternal antibodies passively acquired in utero (anti-rotavi-
rus IgG) may partially, or fully, inhibit the immune response 
to rotavirus vaccine doses given at 6 weeks. Although transpla-
centally acquired antibodies decay exponentially with a half-life 
of approximately 35 to 40 days, there is considerable individual 
variability in the rate of clearance [26]. In addition, the critical 
level at which maternally acquired antibody concentrations are 
low enough to elicit a robust immune response to rotavirus vac-
cines in infants is unknown. One study has examined the clear-
ance rate of passively acquired anti-rotavirus antibodies in 54 
Mexican infants and found a gradual decline until 4 months of 
age and then an increase in anti-rotavirus IgG, likely due to the 
infant’s active immunity to rotavirus infections [27]. Another 
study of the natural history of rotavirus infection found that 
children with maternal antibodies in cord blood were less 
likely to experience symptomatic rotavirus infection before 3 
months of age compared with those without maternal antibod-
ies [28]. Furthermore, one study in India even demonstrated 
the ability of pre-existing anti-rotavirus IgG antibodies in infant 
blood to neutralize the effect of a new rotavirus vaccine (ORV-
116E) [29]. These data suggest it is possible passively acquired 
antibodies could interfere with the immunologic response to 
rotavirus vaccines given to very young infants. However, other 
infant characteristics, including the microbiota of young infants 
in LMICs and other factors affecting enteric immunity, may 
influence any effect of vaccine schedules that is observed.
The implementation of immunization programs for rotavi-
rus vaccines is extremely complex. Currently, the World Health 
Organization recommends that rotavirus vaccines be given as 
soon as possible after 6 weeks of age [30] and that 62% of the 37 
LMICs administering RV1 in their routine immunization pro-
gram use the 6/10-week schedule [2, 31]. The 6/10-week sched-
ule may not be as immunogenic as the 10/14-week schedule, 
which suggests vaccination could start at 10 weeks rather than 
6 week. However, in some LMICs countries, initial vaccination 
is already delayed, and there is concern that starting vaccina-
tion later may lead to prolonged vaccination time or missing 
vaccination altogether. In addition, due to the potential fear of 
increased risk of intussusception [32], there is a recommenda-
tion that RV1 and RV5 be given before 32 weeks if at all possi-
ble [30]. Furthermore, the timing of first rotavirus infection is 
thought to occur early in LMICs (median 6–9 months) [33]. It is 
important that rotavirus vaccines be provided in a timely man-
ner to prevent severe RVGE. Although the additional dose at 14 
weeks could improve immunogenicity, the additional capacity 
and cost associated with this decision may not be justified based 
on the current evidence.
There are some limitations and strengths of this systematic 
review. This is the first review to summarize data on RV1 or 
RV5 schedules and the impact it has on vaccine response among 
children in LMICs. We were limited in our ability to report and 
use the exact sample size for some trials, but we did evaluate the 
effect of schedule on vaccine response. This will be helpful given 
the paucity of data in low-resource settings at this time. In addi-
tion, we were able to present comparisons not directly reported 
in some trials and to estimate seroconversion proportion dif-
ferences and ratios of geometric mean concentrations using the 
same methods to ease comparison across trials. The summari-
zation of these data highlights the importance of assessing the 
effect of RV1 and RV5 schedules on vaccine performance using 
clinical endpoints, because there is the potential that schedules 
could affect the incidence of severe RVGE, and alterations in 
schedules could result in the prevention of more severe RVGE 
episodes.
Table 4. Rotavirus Vaccine Efficacy Against Severe Rotavirus Gastroenteritis Comparing Different Schedules From Trial NCT00241644
Location Schedule Na One Year Efficacy (95% CI) Second Year Efficacy (95% CI) Cumulative Two-Year Efficacy (95% CI)
South Africa 10/14 971 72.2 (40.4 to 88.3) 3 (−43 to 82) 32 (−71 to 75)
6/10/14 973 81.5 (55.1 to 93.7) 76 (−143 to 100) 85 (35 to 98)
Malawi 10/14 525 49.2 (11.1 to 71.7) 2.6 (−101.2 to 52.6) 34.0 (−2 to 57.7)
6/10/14 505 49.7 (11.3 to 72.2) 33.1 (−48.6 to 70.9) 42.3 (8.8 to 64.0)
Abbreviations: CI, confidence interval.
aSample size in each arm for 1-year efficacy analysis.
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CONCLUSIONS
In conclusion, 8 trials have assessed the impact of different RV1 
schedules on vaccine response in LMICs, whereas none have 
reported information for RV5 schedules. Seroconversion pro-
portions and geometric mean concentrations were generally 
lower for the 6/10-week schedule compared with the 10/14-
week schedule. The administration of 3 doses of RV1 on the 
6/10/14-week schedule had similar or slightly higher sero-
conversion proportions, geometric mean concentrations, and 
efficacies against severe RVGE compared with the 10/14-week 
schedule. The commonly used 6/10-week schedule of RV1 in 
LMICs may not be optimal for protection. Further research on 
the effect of RV1 and RV5 schedules using clinical endpoints is 
critical, because if altering schedules could confer better pro-
tection, even small improvements gained by altering vaccine 
schedules could translate into the prevention of thousands of 
severe RVGE episodes each year.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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